Patterns of progression after BRAF+MEK inhibitors (I) could help clinicians in understanding the best treatment strategy among the multiple available options in the BRAFv600 melanoma setting. We analysed outcomes in patients (pts) treated with BRAF+MEK I to characterize pts with rapid progression.
In this multicenter retrospective analisis, 164 consecutive pts affected by BRAFv600 metastatic melanoma and treated with BRAF+MEK I from February 2012 to April 2017 were included.
Overall, 164 patients were enrolled. Baseline LDH was elevated in 68 (41%) pts, baseline number of metastatic organs were 1, 2, 3 and more in 52 (32%), 52 (32%), 29 (18%), and 32 (19%) pts. BRAF+MEK I administered were dabrafenib+trametinib in 151 pts and vemurafenib+cobimetinib in 13 pts, and they were adiministered in first line in 129 (79%) pts. Best response was CR, PR, SD and PD in 27 (16%), 87 (53%), 17 (10%) and 27 (16%) pts. On cutoff date, progression was observed in 104 (63%) pts; 60 (37%) pts still on treatment. mPFS was 9,83 (1-54,7+) months: significant difference in PFS was showed in pts with normal baseline LDH or high LDH (13.2 vs 6.3 months, p
DR and extension of progression during BRAF+MEK I are factors that can be useful to identify pts with lower OS after progression, in addiction to known parameters like LDH and baseline number of metastatic organs.
Clinical trial identification
Legal entity responsible for the study
R. Marconcini: Received payment for consultancy and honoraria for speaking from Bristol-Myers Squibb, MSD, Roche, Novartis. All other authors have declared no conflicts of interest.